Did more digging, care to retract that statement? The WHO does not agree with you.
https://www.who.int/bulletin/archives/78(2)205.pdf (See Table 4)
I will happily admit that most things on this list are rare, but you made a blanket statement that just doesn't fit. Also, these are notoriously difficult to trace back to a cause, years or even decades later. So that these were conclusive back to these vaccines is really impressive scientific work to make that association.
I will also admit that these are vaccines made with much older and less "clean" technology than mRNA vaccines, from a molecular biology standpoint. But that should not be taken as we expect mRNA vaccines to have no long term consequences. I'm happy with LESS, but my expectations will not be NONE.
Interesting information. Thanks for the link. Definitely good to chase down these situations where poorly designed vaccines or incorrect administration have caused problems. TL;DR here is that I disagree with the WHO that these are long-term effects that are not obvious in some individuals in the short term in 3/4 of their stated cases, or they are ADE or vaccine-enhanced disease related (which I've clearly specifically excluded).
#1 "Studies in monkeys have shown that atypical measles is due to failure of the inactivated vaccine to induce a mature Ab or T cell response with production of low avidity Ab that does not effectively neutralize WT virus. After WT MeV infection, large amounts of low avidity Abs are produced that bind, but do not neutralize, MeV, leading to immune complex formation, vasculitis, and pneumonitis".
This falls under the category of antibody-dependent enhancement (or vaccine enhancement) for me, which I've specifically excluded as something that qualifies as a long-term effect at the time of my statement.
It also does not qualify as a long-term effect which is not evident in the short-term. "Experience with the inactivated MeV vaccine emphasized the potential for vaccine-induced enhancement of disease and was withdrawn." In large populations this would be evident right away (even if not immediately identified as related to the vaccine), as individuals were exposed, so a short-term-evident issue, as Fauci said (it would take longer with measles since the disease was not as widespread as SARS2, even at that time).
Measles Vaccine
#2 This sounds like it was hard to attribute to the vaccine. It's not clear, but looks like the precautionary principle applies and high-titer vaccines are apparently no longer used. This one was the hardest one to understand what was going on, or whether there was even a connection. If there is more info on it, it would be interesting to figure it out.
High-titer measles vaccination before 9 months of age and increased female mortality: do we have an explanation? - PubMed.
Differential mortality by measles vaccine titer and sex - PubMed
#3 We've discussed this one already.
ADE is a short-term effect (it will occur in a very short time if exposed to the virus in a very large vaccinated population, even if in some individuals it may take years). Vaccines with ADE have short-term obvious outcomes and we should avoid ADE (which is why I explicitly excluded it from consideration with my original statement, multiple times in this thread, since while they are evident in the short-term at a population level, for some individuals it could be very delayed).
#4 The use of live attenuated or even inactivated vaccines in immunocompromised individuals is contraindicated. This appears to be an immune dysfunction issue and involves live vaccines (it’s the vaccine itself causing problems with the compromised host!).
A fact sheet on bacille Calmette-Guerin (BCG), a vaccine for tuberculosis disease. Provided by the Centers for Disease Control and Prevention (CDC).
www.cdc.gov
"The BCG vaccination itself is believed to be merely safe for a competent immune system. However, a potentially lethal infection could be expected in immunocompromised hosts. In fact immunocompromised patients are vulnerable not only to mycobacterial diseases, but also to adverse complications of BCG vaccine."
This also is an effect that is evident in the short-term in large populations!: "Immunization over the right deltoid muscle with Moreau BCG vaccine (Fundao Ataufo de Paiva, Rio de Janeiro) at 10 days of age had resulted in a nonhealing ulcer."
https://watermark.silverchair.com/2...YL_ygxfb_FjfuR3Hwc75D41GFRRHNvT_ott2Ewr00vkjA
In many individuals this occurred very quickly (even though in some individuals it may have taken years). So it's a short-term effect showing up in the first two months after vaccination in some cases. "the interval between administration of the vaccine and onset of the adverse reactions was within 4 month for three cases, between 4 and 12 months for nine cases (60%), between 12 months and 72 months in three cases." (We're talking about a very large population here - the only way to assess vaccine safety is to look at a lot of outcomes and look for warnings.)
Another paper.
I'm happy with LESS, but my expectations will not be NONE.
I most definitely expect none at this point (which is why I would have waited two months to get the vaccine if I were immediately eligible and not at high risk). What specific issues would you expect with this vaccine? I just don't see anything in the historical record that would suggest we should expect anything at this point (obviously excluding all individuals with issues that arose within 2 months of vaccination).